PGE2 and LTB4 tissue levels in benign and cancerous prostates

Larré, S.; Tran, Nguyen H.; Fan, Cheng; Hamadeh, Hikmat; Champigneulles, J.; Azzouzi, R.; Cussenot, Olivier; Mangin, P.; Olivier, Jean‐Luc

doi:10.1016/j.prostaglandins.2008.05.001

Cited by 51 publications

(35 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Its expression has been associated with promotion of carcinogenesis (44,45), tumor progression (46,47), and apoptosis resistance (48,49). Figure 5 confirmed its role in our model of melanoma progression, while having no effect on the in vitro growth of Tm1 cell proliferation (Fig.…”

Section: Discussionsupporting

confidence: 64%

Leukotriene B4 Creates a Favorable Microenvironment for Murine Melanoma Growth

Bachi

Kim

Nonogaki

et al. 2009

Molecular Cancer Research

View full text Add to dashboard Cite

Chronic inflammation has long been associated with neoplastic progression. Our group had recently shown that the addition of a large number of apoptotic tumor cells to the tumor microenvironment induces a potent acute inflammatory reaction capable of promoting melanoma growth; however, primarily necrotizing cells do not cause such a reaction. Here, we show that potent inflammatory agents, such as lipopolysaccharide (LPS) and carrageenan, also promote growth of subtumorigenic doses of melanoma cells, having no effect on melanoma proliferation in vitro. Inhibition of 5-lipoxygenase (5-LOX) seems to have a pivotal role in this model because caffeic acid and MK886, a FLAP (5-LOX-activating protein) inhibitor, partially hindered tumor growth induced by apoptotic cells or LPS.

show abstract

Section: Discussionsupporting

confidence: 64%

Leukotriene B4 Creates a Favorable Microenvironment for Murine Melanoma Growth

Bachi

Kim

Nonogaki

et al. 2009

Molecular Cancer Research

View full text Add to dashboard Cite

show abstract

“…5G) is likely to operate more efficiently in vivo than in cell culture to confer anoikis resistance to cancer cells. Indeed, increased LTB 4 levels were detected in prostate cancer tissues relative to corresponding normal tissues (13). Such amplification of the action of BLT2 ligands due to recruitment of leukocytes in the inflammatory microenvironment has been proposed to operate in other pathological situations (42).…”

Section: Discussionmentioning

confidence: 99%

“…For example, leukotriene B 4 (LTB 4 ), a 5-LOX-catalyzed product, and 12(S)-hydroxyeicosatetraenoic acid (HETE), a 12-LOX-catalyzed product, are overexpressed in prostate cancer tissues, and these eicosanoids have been suggested to act in an autocrine or paracrine manner in the tumor microenvironment to regulate cell survival, growth, and the metastatic potential of prostate cancer (11,(13)(14)(15). Additionally, growing evidence demonstrates that the LTB 4 cognate receptor BLT2 is highly expressed in various cancers, including colon, ovarian, and pancreatic cancers (16 -19).…”

mentioning

confidence: 99%

Activation of the Leukotriene B4 Receptor 2-Reactive Oxygen Species (BLT2-ROS) Cascade following Detachment Confers Anoikis Resistance in Prostate Cancer Cells

Lee

Kim

2013

Journal of Biological Chemistry

View full text Add to dashboard Cite

Background: Despite the critical role of anoikis resistance in prostate cancer progression, the molecular mechanism causing anoikis resistance remains unclear. Results: BLT2 protects prostate cancer cells against anoikis via a NOX-ROS-NF-B-linked pathway. Conclusion: Activation of the BLT2-linked pathway following cell detachment confers anoikis resistance. Significance: Our findings suggest BLT2 as a key regulator of anoikis resistance in prostate cancer cells.

show abstract

“…Although most cancers lack the enzymes necessary for leukotrienes biosynthesis, they can use LTA 4 released from immune cells to synthesize LTB 4 , which is also a substrate of MRP4. For instance, it has been shown that LTB 4 levels were increased in human colon and prostate cancers (Dreyling et al, 1986;Larré et al, 2008). The increasing LTB 4 can then bind to the BLT1 receptor and activate ERK and PI3k-Akt signaling, resulting in proliferation and cell survival Ihara et al, 2007).…”

Section: The Action Of Mrp4 In Pathophysiological Processesmentioning

confidence: 99%

The Pharmacological and Physiological Role of Multidrug-Resistant Protein 4

Wen

Luo

Huang

et al. 2015

J Pharmacol Exp Ther

View full text Add to dashboard Cite

Multidrug-resistant protein 4 (MRP4), a member of the C subfamily of ATP-binding cassette transporters, is distributed in a variety of tissues and a number of cancers. As a drug transporter, MRP4 is responsible for the pharmacokinetics and pharmacodynamics of numerous drugs, especially antiviral drugs, antitumor drugs, and diuretics. In this regard, the functional role of MRP4 is affected by a number of factors, such as genetic mutations; tissue-specific transcriptional regulations; post-transcriptional regulations, including miRNAs and membrane internalization; and substrate competition. Unlike other C family members, MRP4 is in a pivotal position to transport cellular signaling molecules, through which it is tightly connected to the living activity and physiologic processes of cells and bodies. In the context of several cancers in which MRP4 is overexpressed, MRP4 inhibition shows striking effects against cancer progression and drug resistance. In this review, we describe the role of MRP4 more specifically in both healthy conditions and disease states, with an emphasis on its potential as a drug target.

show abstract

PGE2 and LTB4 tissue levels in benign and cancerous prostates

Cited by 51 publications

References 23 publications

Leukotriene B4 Creates a Favorable Microenvironment for Murine Melanoma Growth

Leukotriene B4 Creates a Favorable Microenvironment for Murine Melanoma Growth

Activation of the Leukotriene B4 Receptor 2-Reactive Oxygen Species (BLT2-ROS) Cascade following Detachment Confers Anoikis Resistance in Prostate Cancer Cells

The Pharmacological and Physiological Role of Multidrug-Resistant Protein 4

Contact Info

Product

Resources

About